Cell cycle kinases as therapeutic _targets for cancer
- PMID: 19568282
- DOI: 10.1038/nrd2907
Cell cycle kinases as therapeutic _targets for cancer
Abstract
Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells. Although several molecules that inhibit cell cycle kinases have been developed and clinically screened as potential anticancer agents, none of these has been approved for commercial use and an effective strategy to specifically control malignant cell proliferation has yet to be established. However, recent genetic and biochemical studies have provided information about the requirement for certain cell cycle kinases by specific tumours and specialized tissue types. Here, we discuss the potential and limitations of established cell cycle kinases as _targets in anticancer drug discovery as well as novel strategies for the design of new agents.
Similar articles
-
[The serine/threonine kinases that control cell cycle progression as therapeutic _targets].Bull Cancer. 2011 Nov;98(11):1335-45. doi: 10.1684/bdc.2011.1467. Bull Cancer. 2011. PMID: 22020767 Review. French.
-
Therapeutic opportunities to control tumor cell cycles.Clin Transl Oncol. 2006 Jun;8(6):399-408. doi: 10.1007/s12094-006-0193-7. Clin Transl Oncol. 2006. PMID: 16790392 Review.
-
Tubulin-associated drug _targets: Aurora kinases, Polo-like kinases, and others.Semin Oncol. 2006 Aug;33(4):436-48. doi: 10.1053/j.seminoncol.2006.04.007. Semin Oncol. 2006. PMID: 16890798 Review.
-
[Novel anti-cancer compounds _targeting the cell cycle].Nihon Yakurigaku Zasshi. 2009 Jan;133(1):27-31. doi: 10.1254/fpj.133.27. Nihon Yakurigaku Zasshi. 2009. PMID: 19145048 Review. Japanese. No abstract available.
-
Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.Molecules. 2021 Aug 26;26(17):5170. doi: 10.3390/molecules26175170. Molecules. 2021. PMID: 34500603 Free PMC article. Review.
Cited by
-
CDK4: A Key Player in the Cell Cycle, Development, and Cancer.Genes Cancer. 2012 Nov;3(11-12):658-69. doi: 10.1177/1947601913478972. Genes Cancer. 2012. PMID: 23634254 Free PMC article.
-
Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells.Oncol Lett. 2012 Sep;4(3):403-407. doi: 10.3892/ol.2012.751. Epub 2012 Jun 11. Oncol Lett. 2012. PMID: 22970038 Free PMC article.
-
Correlation of CCNA1 promoter methylation with malignant tumors: a meta-analysis introduction.Biomed Res Int. 2015;2015:134027. doi: 10.1155/2015/134027. Epub 2015 Jan 15. Biomed Res Int. 2015. Retraction in: Biomed Res Int. 2021 Feb 2;2021:2608067. doi: 10.1155/2021/2608067 PMID: 25654082 Free PMC article. Retracted.
-
Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways.Mol Cell Proteomics. 2016 Sep;15(9):3045-57. doi: 10.1074/mcp.M115.057729. Epub 2016 Jun 30. Mol Cell Proteomics. 2016. PMID: 27364358 Free PMC article.
-
Cdk1 Activates Pre-mitotic Nuclear Envelope Dynein Recruitment and Apical Nuclear Migration in Neural Stem Cells.Dev Cell. 2015 Jun 22;33(6):703-16. doi: 10.1016/j.devcel.2015.04.022. Epub 2015 Jun 4. Dev Cell. 2015. PMID: 26051540 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources